Table 2 Univariable and Multivariate analysis for PFS and OS in 131 de novo mNPC patients
Univariable | Multivariable | |||
|---|---|---|---|---|
HR (95% CI) | p | HR (95% CI) | p | |
Progress-free survival | ||||
Age (≤ 50 vs > 50) | 1.184 (0.742–1.889) | 0.479 | ||
Sex (Female vs Male) | 0.925 (0517–1.655) | 0.792 | ||
Chemotherapy cycles (< 4 vs ≥ 4) | 0298 (0.186–0.477) | < 0.001 | 0.370 (0.215–0.638) | < 0.001 |
IMRT (No vs Yes) | 0.480 (0.303–0.759) | 0.002 | 0.785 (0.461–1.336) | 0.371 |
No. of bone metastasis (≤ 5 vs > 5) | 0.503 (0.316–0.800) | 0.004 | 0.597 (0.383–0.930) | 0.053 |
RT to bone metastases (No vs Yes) | 0.988 (0.620–1.577) | 0.961 | ||
Overall Survival | ||||
Age (≤ 50 vs > 50) | 1.600 (1.009–2.537) | 0.046 | 1.484 (0.929–2.372) | 0.099 |
Sex (Female vs Male) | 1.010 (0.572–1.781) | 0.973 | ||
Chemotherapy cycles (< 4 vs ≥ 4) | 0.269 (0.170–0.425) | < 0.001 | 0.379 (0.224–0.639) | < 0.001 |
IMRT (No vs Yes) | 0.374 (0.235–0.595) | < 0.001 | 0.624 (0.369–1.054) | 0.078 |
No. of bone metastasis (≤ 5 vs > 5) | 0.449 (0.282–0.715) | 0.001 | 0.567 (0.352–0.915) | 0.020 |
RT to bone metastases (No vs Yes) | 0.914 (0.572–1.459) | 0.706 | ||